Company profile
CULLINAN THERAPEUTICS, INC.
NASDAQ:CGEMBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VK-2019 | phase1_2 | — | 1 | terminated |
| ZIPALERTINIB | phase1_2 | — | 1 | active |
| ISUVENTATUG | phase1 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04036682 | phase1_2 | active_not_recruiting | 2019-10-31 | 2025-10-13 | Cullinan Therapeutics Inc. | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer |
| NCT07722767 | phase1 | not_yet_recruiting | 2026-10-15 | 2027-09-30 | Cullinan Therapeutics Inc. | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients |
| NCT07738822 | phase1_2 | not_yet_recruiting | 2026-12-01 | 2029-01-01 | Cullinan Therapeutics Inc. | A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA |
| NCT06381141 | phase1 | active_not_recruiting | 2024-09-03 | 2026-09-01 | Cullinan Therapeutics Inc. | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma |
| NCT05117476 | phase1 | active_not_recruiting | 2021-10-29 | 2026-03-01 | Cullinan Therapeutics Inc. | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors |
FDA applications (0)
No records yet.